Patients Undergoing Dental Surgery who are Taking Antiplatelet Medications

DR. ALI ABDULLAH A AL AMRI      Dr. Saleh Ali Alanazi
Dr. Hussain Hamdan Ali Turi      Dr. Munif Odhayb Alruwaili

Abstract
For the undergoing dental surgery patients taking antiplatelet medications, physicians and dentists must weigh the bleeding risks in continuing antiplatelet medications versus the thrombotic risks in interrupting antiplatelet medications. Bleeding complications requiring more than local measures for hemostasis are rare after dental surgery in patients taking antiplatelet medications. Conversely, the risk for thrombotic complications after interruption of antiplatelet therapy for dental procedures apparently is significant, although small. When a clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, the decision comes down to “bleed or die.” That is, there is a remote chance that continuing antiplatelet therapy will result in a (nonfatal) bleeding problem requiring more than local measures for hemostasis versus a small but significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) thromboembolic complication. The decision is simple: It is time to stop interrupting antiplatelet therapy for dental surgery.

Acknowledgment
This research has been prepared through cooperation and concerted efforts of the researchers in collecting and compiling the necessary data; each researcher with a certain role. Hence, this research was conducted with the joint efforts of the researchers; DR. ALI ABDULLAH A AL AMRI as main authors, and Dr. Saleh Ali Alanazi, Dr. Hussain Hamdan Ali Turi and Dr. Munif Odhayb Alruwaili as co-authors. The researchers thank everyone who contributed to providing the data and information that helped to accomplish this research.

1.1 Introduction
More than 2000 years ago has witnessed the history of aspirin (acetylsalicylic acid), when Hippocrates recommended chewing on willow leaves (which contain salicylic acid) during childbirth for analgesia. In 1899, the chemist Felix Hoffman of Bayer AG (Leverkusen, Germany) was the first to isolate pure acetylsalicylic acid, later calling it “Aspirin” for commercial manufacture and sale. Since then, Bayer AG lost or sold its rights to the trademark, and the “wonder drug” aspirin is widely used for its analgesic, antipyretic, anti-inflammatory, and anti-thrombotic effects. Aspirin’s antithrombotic indications include atrial fibrillation, history of angina or myocardial infarction, coronary artery disease prevention, history of coronary bypass surgery, and percutaneous coronary intervention and stent implantation.

Some of the newer agents are associated with greater antithrombotic efficacy but also higher bleeding risks than aspirin. When dental surgery is contemplated in patients taking 1 or more of these medications, dentists and physicians must weigh the potential bleeding risks in continuing the medications versus the thromboembolic risks in interrupting them before dental surgery (Ferrari, Benhamou, Cerboni & Marcel, 2005). Dentists frequently recommend aspirin withdrawal before dental surgery, even without consulting the patient’s physician. Both physicians and dentists frequently overestimate the bleeding risks of dental surgery in patients continuing antiplatelet medications and underestimate the thrombotic risks of interrupting antiplatelet therapy for dental procedures (Van Diermen, Waal & Hoogvliets, 2013).

Dental surgery is unlike other types of surgery: Major vessels are unlikely to be encountered, and the perioperative and postoperative surgical sites are easily accessible to local measures for hemostasis, such as biting on gauze, absorbable gelatin sponges, and sutures. As early as 1987, Salzman stated, “The hemostatic defect induced by aspirin in patients with otherwise normal hemostasis is usually minor (Salzman, 1987).

There have been many reports of patients continuing antiplatelet agents while undergoing dental surgery. Of at least 1283 patients taking single or dual antiplatelet agents undergoing at least 2343 dental surgical procedures, including at least 2308 single and multiple, simple, and surgical dental extractions in at least 1334 visits, no more than 35 patients (2.7% of patients and 2.6% of visits) had bleeding complications requiring local measures for hemostasis and only 2 patients (0.2%) required more than local measures for hemostasis. It should be noted that the risks of bleeding may differ on the basis of the antiplatelet agent and the regimen used.

Although some of the newer agents and regimens may be associated with higher bleeding risks, none of the patients taking non-aspirin or dual antiplatelet agents had bleeding complications that required more than local hemostatic measures.
1.2 Literature Review
In 1974, Lemkin et al reported on a patient taking 12 to 20 daily aspirin tablets (dosage unreported) who had uncontrolled bleeding after undergoing 18 extractions. The history included ethanol abuse, but the patient denied recent alcohol ingestion. Sutures and oxidized cellulose were unsuccessful for hemostasis, and the patient was admitted to the hospital the next day. Hemostasis was achieved after a platelet transfusion. Although the dose is unreported, 12 to 20 daily aspirin tablets were probably more than therapeutic and almost certainly more than the single daily tablet typically prescribed today for anti-thrombosis.

In 1997, Thomason et al reported on a kidney transplant recipient who underwent a gingivectomy for gingival overgrowth and was taking aspirin 150 mg/day, in addition to cyclosporine, azathioprine, and amlodipine. Hemostasis was achieved with pressure from gauze after the lower anterior gingivectomy, but after the upper anterior gingivectomy, there was excessive hemorrhage uncontrolled with local measures, and the patient was admitted to the hospital for a platelet transfusion, after which hemostasis was achieved. It is not clear that the relatively low dose of aspirin was the cause of the postoperative bleeding.

Although the evidence shows that dental surgery can be accomplished with minimal bleeding risk in patients receiving single or dual antiplatelet medications, some have recommended a 7- to 10-day interruption of antiplatelet therapy for dental extractions (Ogle & Hernandez, 1998). There are various levels of thrombotic risk associated with continuous antiplatelet therapy interruption, depending on the reason for the antithrombotic therapy. For example, there is a relatively low risk of thrombotic complications when single antiplatelet therapy is withdrawn in primary prevention patients versus a relatively high risk when dual antiplatelet therapy is withdrawn in patients after recent percutaneous coronary intervention. Whenever antiplatelet therapy is interrupted, regardless of the reason, there is at least some increased risk of thrombotic complications. In a case-control study of Biondi-Zoccai et al, 513 patients who had a first-ever prescription of low-dose aspirin over a 7-year period, García Rodríguez et al determined that patients who had recently interrupted aspirin were significantly more likely to have a myocardial infarction than patients whose aspirin therapy was continued. “For every 1000 patients, over a period of one year there were about four more cases of non-fatal myocardial infarction among patients who discontinued treatment with low dose aspirin (recent discontinuers) compared with patients who continued treatment.” García Rodríguez et al also showed a 40% increased risk of ischemic stroke or transient ischemic attack after withdrawal of aspirin within 1 to 3 months in patients with cardiovascular disease or cerebrovascular disease.

Biondi-Zoccai et al conducted a meta-analysis of 50,279 patients in 6 studies and concluded that aspirin nonadherence or withdrawal was associated with a 3 times higher risk of a major adverse cardiac event versus continuing aspirin therapy. The authors concluded that the withdrawal of aspirin can have an “ominous prognostic implication” in patients at moderate or high risk for coronary artery disease. Sibon and Orgogozo studied 289 patients with cerebral infarction and found that 13 of these patients had had antiplatelet drug interruption within 1 month before the ischemic stroke. Maulaz et al conducted a case-control study of 309 patients admitted for stroke or transient ischemic attack who had been on aspirin therapy versus 309 controls on aspirin with history of stroke but no stroke or transient ischemic attack within 6 months. There were 13 patients who had discontinued aspirin in the 4 weeks before the ischemic event, of whom 7 had been instructed to withdraw aspirin by a physician for a surgical procedure or because the physician thought aspirin was not necessary. The authors concluded that preoperative withdrawal of aspirin therapy “may not always be the best solution” before surgical procedures.

1.3 Data discussion
Although most studies of antiplatelet medication interruption for dental procedures have shown no thrombotic complications (Table 1), there have been some cases of thrombotic complications when antiplatelet medications were interrupted for dental procedures (Table 1).
The authors concluded that rates of stent thrombosis or acute myocardial infarction are low but not insignificant after drug-eluting stent implantation. At least 17 of 324 patients (5%) whose antiplatelet medications were interrupted for dental surgery had thrombotic complications. The actual overall risk of antiplatelet cessation is probably significantly less than 5%, but more than zero. In the study by Kovacic et al, the rate of thrombotic complications in patients whose antiplatelet medications were interrupted for any reason (not just dental procedures) was approximately 1% of all cessations, and even this number seems high. Patients receiving dual antiplatelet therapy after drug-eluting stent implantation are at higher risk than many other patients receiving antiplatelet therapy, so it is difficult to extrapolate these results to other patients receiving antiplatelet therapy, but because the risk of hemorrhage after dental surgery in patients receiving antiplatelet medications is extraordinarily low, antiplatelet medication interruption for dental procedures exposes patients to an unnecessarily increased risk (although still low) of serious thrombotic complications.

### 1.4 National Medical and Dental Group Recommendations for Dental Surgery in Patients Taking Antiplatelet Medications and Recommendations of Other Reviews

The American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association have stated that single or dual antiplatelet therapy should not be interrupted for dental procedures, concluding, “Given the relative ease with which the incidence and severity of oral bleeding can be reduced with local measures during surgery (e.g., absorbable gelatin sponge and sutures) and the unlikely occurrence of bleeding once an initial clot has formed, there is little or no indication to interrupt antiplatelet drugs for dental procedures.” The American College of Chest Physicians also recommends continuing aspirin for dental surgery. In reviewing the literature in 2007, Brennan et al concluded that dental extractions can be performed with minimal bleeding risk in patients on continuous low-dose aspirin. In “extenuating” circumstances, when antiplatelet therapy should be interrupted, then the interruption should be for no more than 3 days to minimize the risk of thrombosis.

Napeñas et al conducted a literature review of bleeding complications in dental patients taking antiplatelet agents in 2013, focusing on 15 studies, which showed there is not a significantly increased risk of postoperative bleeding complications in patients receiving single or dual antiplatelet therapy, although there may be increased bleeding risk in patients receiving combination antiplatelet and anticoagulant therapy. The authors concluded there is no need to stop single or dual antiplatelet therapy for invasive dental procedures, and local measures are adequate for hemostasis.

van Diermen et al searched the literature and expert recommendations from 2007 to 2012 and concluded that antithrombotic medications including dual antiplatelet therapy should not be interrupted for simple dental extractions. In “extenuating” circumstances, when antiplatelet therapy should be interrupted, then the interruption should be for no more than 3 days to minimize the risk of thrombosis.
procedures, including extractions.

1.5 Conclusions
When a clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, the decision comes down to “bleed or die.” That is, there is a remote (≤0.2%) chance that continuing antiplatelet therapy will result in a (nonfatal) bleeding problem requiring more than local measures for hemostasis versus an unknown but significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) thromboembolic complication.

The decision is fairly simple: It is time to stop interrupting antiplatelet therapy for dental surgery.

References


